Search research articles
Contact Us
Filters
Showing results (171-180 of 213) with videos related to
Page
of 22
Sort By:
Cancer Research
|
January 11, 1992
Antitumor activity of basic fibroblast growth factor-saporin mitotoxin in vitro and in vivo
J G Beitz, P Davol, J W Clark, et al.
Cancer Chemotherapy and Pharmacology
|
October 29, 2000
A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion
J G Supko, T J Lynch, J W Clark, et al.
International Journal of Cancer
|
August 15, 1984
Type-I HTLV antibody in urban and rural Ghana, West Africa
R J Biggar, C Saxinger, C Gardiner, et al.
Lasers in Surgery and Medicine
|
January 1, 1989
Comparative study of suture and laser-assisted anastomoses in rat sciatic nerves
T A Benke, J W Clark, P J Wisoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 1991
The in vivo immunomodulatory effects of recombinant interferon gamma plus recombinant tumor necrosis factor-alfa
W J Urba, W C Kopp, J W Clark, et al.
British Journal of Cancer
|
November 27, 1999
The potential role for prolactin-inducible protein (PIP) as a marker of human breast cancer micrometastasis
J W Clark, L Snell, R P Shiu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 24, 2006
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
D Strumberg, A Awada, H Hirte, et al.
Journal of the American Dental Association (1939)
|
September 1, 1986
Intraoral effects of a fluoride-releasing device on acid-softened enamel
R E Corpron, J W Clark, A Tsai, et al.
The Journal of Steroid Biochemistry and Molecular Biology
|
December 1, 1996
1alpha,25-dihydroxy-24-oxo-16-ene vitamin D3, a metabolite of a synthetic vitamin D3 analog, 1alpha,25-dihydroxy-16-ene vitamin D3, is equipotent to its parent in modulating growth and differentiation of human leukemic cells
M L Siu-Caldera, J W Clark, A Santos-Moore, et al.
The New England Journal of Medicine
|
June 2, 1988
Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies
R G Steis, J W Smith, W J Urba, et al.
Page
of 22
Search research articles
Search
Showing results (171-180 of 213) with videos related to
Sort By:
Page
of 22
Cancer Research
|
January 11, 1992
Antitumor activity of basic fibroblast growth factor-saporin mitotoxin in vitro and in vivo
J G Beitz, P Davol, J W Clark, et al.
Cancer Chemotherapy and Pharmacology
|
October 29, 2000
A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion
J G Supko, T J Lynch, J W Clark, et al.
International Journal of Cancer
|
August 15, 1984
Type-I HTLV antibody in urban and rural Ghana, West Africa
R J Biggar, C Saxinger, C Gardiner, et al.
Lasers in Surgery and Medicine
|
January 1, 1989
Comparative study of suture and laser-assisted anastomoses in rat sciatic nerves
T A Benke, J W Clark, P J Wisoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 1991
The in vivo immunomodulatory effects of recombinant interferon gamma plus recombinant tumor necrosis factor-alfa
W J Urba, W C Kopp, J W Clark, et al.
British Journal of Cancer
|
November 27, 1999
The potential role for prolactin-inducible protein (PIP) as a marker of human breast cancer micrometastasis
J W Clark, L Snell, R P Shiu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 24, 2006
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
D Strumberg, A Awada, H Hirte, et al.
Journal of the American Dental Association (1939)
|
September 1, 1986
Intraoral effects of a fluoride-releasing device on acid-softened enamel
R E Corpron, J W Clark, A Tsai, et al.
The Journal of Steroid Biochemistry and Molecular Biology
|
December 1, 1996
1alpha,25-dihydroxy-24-oxo-16-ene vitamin D3, a metabolite of a synthetic vitamin D3 analog, 1alpha,25-dihydroxy-16-ene vitamin D3, is equipotent to its parent in modulating growth and differentiation of human leukemic cells
M L Siu-Caldera, J W Clark, A Santos-Moore, et al.
The New England Journal of Medicine
|
June 2, 1988
Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies
R G Steis, J W Smith, W J Urba, et al.
Page
of 22